Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

AstraZeneca · Phase 3 · Terminated · Enrollment 13

NCT03419624

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Dapagliflozin plus Exenatiden/rn/rn/rn/r
Placebo plus Placebon/rn/rn/rn/r
Placebo plus Exenatiden/rn/rn/rn/r

Not shown

  • Dapagliflozin plus Exenatide: endpoint not reported
  • Placebo plus Placebo: endpoint not reported
  • Placebo plus Exenatide: endpoint not reported